Used in targeted cancer therapies, particularly in solid tumors such as prostate, colorectal, and breast cancers where EphB2 receptor is overexpressed. This antibody serves as a reference tool in research and development of monoclonal antibody-based treatments, aiding in the validation of EphB2 as a therapeutic target. It is also employed in diagnostic assays to detect EphB2 expression levels in tumor tissues, supporting patient stratification in clinical studies. Additionally, it plays a role in antibody-drug conjugate (ADC) platforms by enabling targeted delivery of cytotoxic agents to EphB2-positive cells, minimizing damage to healthy tissues.